14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
NMR vs LPLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Nomura Holdings, Inc (NMR) captures the overall head-to-head institutional edge over LPL Financial Holdings Inc. (LPLA) on higher Unified Composite conviction (44.5/100 HOLD vs. 54.0/100 HOLD) after splitting the core matrix 6–3 (led by Profitability & Quality, R&D & Supply-Chain Moat), while LPLA wins 3–2 across the 6-pillar growth and valuation breakdown. NMR trades at $9.34 (12.7x Forward P/E, 25.1% operating margin) versus LPLA at $283.19 (9.8x Forward P/E, 10.8% operating margin).
Composite vs. Pillar Nuance: While LPLA currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. NMR 44.5/100 HOLD), NMR captures the overall institutional head-to-head verdict (6–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (25.1% vs. 10.8% operating margin) and revenue trajectory (+17.9% vs. +17.8% YoY).
Technical & Structure Timing Caution: NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile LPLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NMR vs LPLA. Trailing 12-month operating profitability (NMR 25.1% vs LPLA 10.8%) and valuation multiples (NMR 12.7x vs LPLA 9.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Capital Markets value chain with $22.8B market capitalization and 10.8% operating margin.
OpEx & R&D Reinvestment18.8% of Rev ($3.76B)
90D Engineering Disclosures0 Published
Investor FAQ NMR vs LPLA Key Questions & Quantitative Answers
As of Nov 17, 2026, Nomura Holdings, Inc (NMR) captures the overall head-to-head institutional edge over LPL Financial Holdings Inc. (LPLA) on higher Unified Composite conviction (44.5/100 HOLD vs. 54.0/100 HOLD) after splitting the core matrix 6–3 (led by Profitability & Quality, R&D & Supply-Chain Moat), while LPLA wins 3–2 across the 6-pillar growth and valuation breakdown. NMR trades at $9.34 (12.7x Forward P/E, 25.1% operating margin) versus LPLA at $283.19 (9.8x Forward P/E, 10.8% operating margin). Composite vs. Pillar Nuance: While LPLA currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. NMR 44.5/100 HOLD), NMR captures the overall institutional head-to-head verdict (6–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (25.1% vs. 10.8% operating margin) and revenue trajectory (+17.9% vs. +17.8% YoY). Technical & Structure Timing Caution: NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile LPLA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LPLA leads the Growth & Scale pillar: NMR posts +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin), compared with LPLA at +17.8% YoY revenue growth and +39.4% YoY earnings growth on $20.0B TTM revenue (29.6% gross margin, 10.8% operating margin). On trailing 12-month operating scale, NMR generates $14.9B in USD-normalized revenue versus $20.0B for LPLA. In operating R&D and SG&A reinvestment, NMR deploys 52.3% of Rev ($7.77B) (0 90-day corporate R&D disclosures) versus 18.8% of Rev ($3.76B) (0 disclosures) for LPLA.
LPLA screens cheaper on headline valuation multiples. NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin), whereas LPLA trades at 9.8x Forward P/E, 16.8x Trailing P/E, 0.37x PEG, and 1.1x EV/Revenue (10.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMR (11.5% ROE) versus LPLA (25.7% ROE) capital efficiency.
In options market volatility and institutional positioning, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk). By comparison, LPLA carries 29.5% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.58β · 64% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.